Picture loading failed.

Pre-Made Clazakizumab biosimilar, Whole mAb, Anti-IL6 Antibody: Anti-BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Clazakizumab (formerly ALD518 and BMS-945429), an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6. Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-110-1mg 1mg 3090
GMP-Bios-ab-110-10mg 10mg 21890
GMP-Bios-ab-110-100mg 100mg 148000
GMP-Bios-ab-110-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Clazakizumab biosimilar, Whole mAb, Anti-IL6 Antibody: Anti-BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6 therapeutic antibody
INN Name Clazakizumab
TargetIL6
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesAlder Biopharmaceuticals;Cedars-Sinai Medical Center;Medical University of Vienna;Vitaeris
Conditions Approvedna
Conditions ActiveRenal transplant rejection;COVID-19
Conditions DiscontinuedAnaemia;Cachexia;Fatigue;Stomatitis;Crohn's disease;Graft-versus-host disease;Inflammation;Psoriatic arthritis;Rheumatoid Arthritis
Development Techna